Qlife Holding AB ("Qlife" or the "Company") today announces the outcome of the exercise of warrants series TO 6 that were issued in connection with Qlife's directed issues in August 2024 (the "Directed Issues"). A total of 2,371,026 shares were subscribed for through the exercise of warrants, corresponding to an exercise rate of 100 percent. Qlife will receive proceeds of approximately SEK 4.7 million before transaction costs.

"I want to sincerely thank all of our shareholders for their continued support. We are thrilled by the strong interest in the warrants, which have now been fully subscribed. With this backing, we are better positioned than ever to advance our strategy and continue creating long-term value for our shareholders."- Says Thomas Warthoe, CEO of Qlife.

The outcome shows that 2,371,026 warrants were exercised for subscription of 2,371,026 shares, corresponding to an exercise rate of 100 percent. Exercised warrants have been replaced with interim shares pending registration with the Swedish Companies Registration Office.

In total, Qlife issued 2,371,026 warrants in the Directed Issues, One (1) warrant series TO 6 entitled the holder to subscribe for one (1) new share in the Company during the period 1 September 2025 - 19 September 2025 at an exercise price corresponding to the lower of (i) SEK 3.15 and (ii) the lowest subscription price applied in any rights issues carried out by the company during the term of the warrants, but not less than the quota value of the share.

On 29 January 2025 the board of directors in Qlife resolved on a rights issue of approximately SEK 11.8 million (the "Rights Issue"). The subscription price in the Rights Issue was 2.0 SEK per share. As a result of the Rights Issue, a recalculation was carried out in accordance with the terms and conditions of the Company's warrants of series TO 6, adjusting the subscription price per share each warrant entitles the holder to subscribe for. All other terms and conditions for the warrants of series TO 6 remain unchanged, such as the exercise period and the total number of outstanding warrants remains unaffected by the Rights Issue and recalculation. The new subscription price per share upon exercising the warrants of series TO 6 was set at SEK 2.0, corresponding to the subscription price per share in the Rights Issue. The number of shares each warrant entitled the holder to subscribe for remained unchanged.

Through the exercise of the warrants the Company receives approximately SEK 4,7 million before transaction costs. The total number of shares in Qlife increases by 2,371,026, from 13,308,495 to 15,679,521. The share capital in Qlife increases by SEK 379,364.16, from SEK 2,129,359.20 to SEK 2,508,723.36, resulting in a dilution effect of approximately 15.1 percent.

Advisors

Eminova Partners Corporate Finance AB acted as financial advisor and Moll Wendén Advokatbyrå AB acted as legal advisor in connection with the exercise of the warrants. Eminova Fondkommission AB acted as issue agent.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The Company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.  

Important information

The publication, release or distribution of this press release in certain jurisdictions may be restricted by law and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and observe any such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in each jurisdiction. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved or reviewed by any regulatory authority in any jurisdiction. Nor does this press release constitute an exemption document in the form prescribed by the Prospectus Regulation Annex IX.

This press release does not constitute an offer or invitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an applicable exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States of America, Canada, Australia, New Zealand, Japan, Hong Kong, South Korea, Singapore, South Africa, Switzerland, Russia or Belarus or any other jurisdiction where such announcement, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require additional registration or other measures than those required by Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities laws.

This press release does not identify or purport to identify any risks (direct or indirect) that may be associated with an investment in new shares. This press release does not constitute an invitation to underwrite, subscribe or otherwise acquire or transfer securities in any jurisdiction. This press release does not constitute a recommendation for any investor's decision. Each investor or potential investor should conduct its own investigation, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities may go down as well as up and past performance is no guide to future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or expectations regarding the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by the use of words such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, the negatives thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or that they are accurate. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes could differ materially from those in the forward-looking statements for a variety of reasons. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements contained in this press release are accurate and any reader of this press release should not place undue reliance on the forward-looking statements contained in this press release. The information, opinions and forward-looking statements expressed or implied herein are made only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required to do so by law or the rules of Nasdaq First North Growth Market.